Please sign in to follow a disease.
Serous adenocarcinoma
MONDO:0005278An adenocarcinoma that is characterized by the presence of papillary patterns and cellular budding. Psammoma bodies may be present. Representative examples include cervical serous adenocarcinoma, endometrial serous adenocarcinoma, ovarian serous adenocarcinoma, and primary peritoneal serous adenocarcinoma.
Also known as: serous adenocarcinoma, serous carcinoma, serous cystadenocarcinoma, serous cystadenocarcinoma, NOS (morphologic abnormality)
2977 clinical trials for this condition and its sub-types, 6 tagged with Serous adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Serous adenocarcinoma
-
Ovarian serous adenocarcinoma 199 trials · 203 incl. sub-types
3 sub-types
-
Fallopian tube serous adenocarcinoma 71 trials
-
Peritoneal serous adenocarcinoma 2 trials · 39 incl. sub-types
1 sub-type
- Primary peritoneal serous adenocarcinoma 36 trials · 38 incl. sub-types Sub-types →
-
Endometrial serous adenocarcinoma 36 trials
-
Serous cystadenocarcinoma 1 trial · 5 incl. sub-types
3 sub-types
- Ovarian serous cystadenocarcinoma 4 trials
- Pancreatic serous cystadenocarcinoma 0 trials
- Papillary serous cystadenocarcinoma 0 trials
-
Cervical serous adenocarcinoma 0 trials
1 sub-type
-
New drug cocktails show promise against tough endometrial cancer
Disease control OngoingThis study tests several drug combinations in women with endometrial cancer that has returned or not responded to treatment. The drugs work by blocking cancer cell growth or helping the immune system attack tumors. The goal is to see if these combinations can slow or stop the can…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat ovarian cancer
Disease control OngoingThis phase II trial is testing whether the combination of ribociclib (a targeted cancer drug) and letrozole (a hormone therapy) can shrink or stabilize tumors in women with recurrent low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum. The study enrolled 51 wom…
Phase 2 • Sponsor: Gynecologic Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC